CVA Family Office LLC Acquires 2,296 Shares of Johnson & Johnson (NYSE:JNJ)

CVA Family Office LLC boosted its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 36.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,610 shares of the company's stock after acquiring an additional 2,296 shares during the period. CVA Family Office LLC's holdings in Johnson & Johnson were worth $1,428,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Powers Advisory Group LLC boosted its stake in shares of Johnson & Johnson by 1.7% in the 1st quarter. Powers Advisory Group LLC now owns 9,755 shares of the company's stock valued at $1,618,000 after purchasing an additional 164 shares during the last quarter. Krilogy Financial LLC lifted its holdings in Johnson & Johnson by 12.0% in the first quarter. Krilogy Financial LLC now owns 11,893 shares of the company's stock valued at $1,972,000 after buying an additional 1,272 shares during the period. Tudor Financial Inc. boosted its position in Johnson & Johnson by 2.3% during the first quarter. Tudor Financial Inc. now owns 6,583 shares of the company's stock valued at $1,092,000 after acquiring an additional 147 shares during the last quarter. West Branch Capital LLC raised its position in shares of Johnson & Johnson by 7.9% in the 1st quarter. West Branch Capital LLC now owns 25,400 shares of the company's stock worth $4,212,000 after acquiring an additional 1,866 shares in the last quarter. Finally, Defined Wealth Management LLC lifted its stake in shares of Johnson & Johnson by 2.9% in the 1st quarter. Defined Wealth Management LLC now owns 3,153 shares of the company's stock valued at $523,000 after purchasing an additional 90 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 1.8%

JNJ stock traded down $2.84 during mid-day trading on Tuesday, reaching $152.38. 6,406,138 shares of the company traded hands, compared to its average volume of 7,958,458. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm's 50 day moving average price is $154.03 and its 200 day moving average price is $153.69. The stock has a market cap of $366.65 billion, a price-to-earnings ratio of 16.95, a P/E/G ratio of 2.35 and a beta of 0.42. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.41%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their target price for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Finally, Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.